<table>
<thead>
<tr>
<th>Clinical Trial</th>
<th>Location(s)</th>
<th>Current Status</th>
<th># of Patients</th>
<th>Taking sirolimus allowed?</th>
<th>Travel funds available?</th>
<th>Study Coordinator(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Observational &amp; Registry Studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| NIH | Bethesda, MD | Ongoing | NA | NA | YES | Tat‘Yana Worthy, RN, MSN  
worthyt@nhlbi.nih.gov  
301-827-1376 |
| NDRI | Any | Ongoing | NA | NA | NA | Mary Sue Wentzel,  
mwentzel@thelamfoundation.org  
(513) 777-6889 |
| MIDAS | Palo Alto, CA, Denver, CO, Jacksonville, FL, Atlanta, GA, Chicago, IL, Boston, MA, Ann Arbor, MI, Rochester, MN, St. Louis, MO, Rochester, NY, Cincinnati, OH, Cleveland, OH, Philadelphia, PA, Charleston, SC, Nashville, TN, Dallas, TX, Houston, TX, Salt Lake City, UT, Seattle, WA, Portland, OR | Not Enrolling - ACTIVE | 600 | NA | NO | All Sites: Susan McMahan,  
susan.mcmahan@uc.edu  
(513) 558-4376 (o) |
| U01 | Bethesda, MD | Ongoing | 24 | NA | YES | Tat‘Yana Worthy, RN, MSN  
worthyt@nhlbi.nih.gov  
301-827-1376 |
| **Interventional Studies** |
| MILED | Los Angeles, CA, Palo Alto, CA, Denver, CO, Atlanta, GA, Chicago, IL, Boston, MA, New York, NY, Cincinnati, OH, Philadelphia, PA, Seattle, WA | Enrolling through 06/2020 | 60 | NO | YES | All Sites: Sue McMahan,  
susan.mcmahan@uc.edu  
(513) 558-4376 (o) |
| Inhaled Albuterol | Bethesda, MD | Enrolling through 11/2021 | 150 | YES | YES | Tat‘Yana Worthy, RN, MSN  
worthyt@nhlbi.nih.gov  
301-827-1376 |
The purpose of this document is to summarize all currently enrolling clinical research trials and studies for LAM patients. For more detailed information about all ongoing, currently enrolling, and upcoming clinical research please visit TheLAMFoundation.org and review the Current Clinical Trials and Studies page.

**Ongoing Trials and Studies**
These trials include observational and registry studies.

- **National Institutes of Health (NIH) - Study of the Disease Process of LAM**
  Principal Investigator: Joel Moss, MD, PhD

- **National Disease Research Interchange (NDRI) – Tissue Donation**

- **Multi-Center International Durability and Safety of Sirolimus in LAM (MIDAS)**
  ACTIVE - NOT ENROLLING  Principal Investigator: Francis X. McCormack, MD

- **Discovery of Sirolimus Sensitive Biomarkers in Blood (U01)**
  Principal Investigator: Joel Moss, MD, PhD

**Interventional Trials and Studies**
These trials require patients to take an investigational research drug or placebo pill.

- **Multicenter Interventional LAM Early Disease (MILED)**
  Principal Investigator: Francis X. McCormack, MD

- **Bronchodilator Effects of Nebulized Versus Inhaled Albuterol In Subjects With Lymphangioleiomyomatosis (Inhaled Albuterol)**
  Principal Investigator: Joel Moss, MD, National Heart, Lung, and Blood Institute (NHLBI)